The Cannigma

APRIL 12, 2023

MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.

Sleep 133

Sleep Data Tincture Collective 133

Cannabis Law Report

APRIL 17, 2023

. — Oregon lawmakers are currently considering a bill that would require licensed psilocybin providers to submit data about their client’s demographics to state health officials.

Data 52

Data Collective Therapy Patients 52

Cannabis Law Report

JUNE 21, 2021

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

NORML

FEBRUARY 1, 2019

Patients authorized to legally use medical cannabis frequently substitute it in place of benzodiazepines, according to a pair of new studies published this week. According to data compiled by the US Centers for Disease Control, the drug was attributed to over 11,500 overdose deaths in 2017.

Patients 233

Patients Chronic Pain Therapy Data 233

Cannabis Law Report

JANUARY 5, 2022

Starting this week, the Cannabis Control Commission (Commission)’s Open Data Platform composed of application and license, agent registration and ownership, and sales and product distribution information is now available on their main website at. MassCannabisControl.com/open- data. View the Open Data Platform.

Data 98

Data Treatment Programs Patients 98

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”

Clinical Trials 240

Clinical Trials Chronic Pain Cannabinoids Patients 240

Veriheal

JANUARY 16, 2024

Instead of directly surveying the young patients, they reached out to their caregivers – the individuals who deeply understand the daily routines, challenges, and treatments of these children. This paves the way for a more integrated approach to care where CBD can be used alongside traditional treatments to optimize patient outcomes.

Patients 113

Patients CBD Treatment Therapy 113

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

United Patients Group

JUNE 8, 2023

A high-quality patient experience is paramount in any healthcare setting. Satisfied patients are more likely to trust their healthcare providers. It encourages patients to ask questions, provide accurate information, and participate in shared decision-making, leading to better treatment adherence and overall care quality.

Patients 52

Patients Data Collective Environment 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

The Cannigma

SEPTEMBER 18, 2023

So it’s not surprising that products that combine cannabis and melatonin are making their way into legal marketing – and according to real world data gathered in a recent campaign on The Cannigma, it’s a winning combination. More sleeping hours and less wakeups There was a clear improvement in sleep measures within the study.

Sleep 83

Sleep Data THC CBD 83

NORML

OCTOBER 10, 2019

Some four in ten adults who reported using both marijuana and opioids within the past year acknowledge either decreasing or ceasing their consumption of opioids as a result of substituting cannabis, according to an analysis of survey data published in the journal PLOS One. ” authors concluded.

Patients 230

Patients Consumption Data Marijuana 230

Cannabis Life Network

JANUARY 16, 2022

People with AD are roughly around the age of 65 and according to recent data, increase every five to six years. The post Could CBD Help Patients With Alzheimer’s? It’s the most common cause of dementia, a term for memory loss. Although there isn’t a cure for Alzheimer’s, medical experts are continuing to […].

Patients 103

Patients CBD Data Treatment 103

The Fresh Toast

MAY 6, 2020

Medical Marijuana Leads To Less Hospitalizations For IBS Patients. New data shows IBS patients who used marijuana experienced less hospitalizations and shorter visits compared to non-users. The post Medical Marijuana Leads To Less Hospitalizations For IBS Patients appeared first on The Fresh Toast.

Patients 138

Patients Marijuana Data CBD 138

NORML

NOVEMBER 25, 2019

Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One.

Chronic Pain 273

Chronic Pain Patients Therapy Data 273

SpeedWeed

JUNE 15, 2021

Ten Years Of Patient Data Supports Israeli Company’s Global Expansion – Cannabis Business Executive – Cannabis and Marijuana industry news. The post Ten Years Of Patient Data Supports Israeli Company’s Global Expansion – Cannabis Business Executive appeared first on SpeedWeed.

Data 40

Data Patients Business Cannabis 40

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.

Data 100

Data Research and Development Patients Strains 100

Cannabis Law Report

AUGUST 23, 2022

A panel of Commonwealth Court judges has ordered the Wolf administration to reveal how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment. The newsroom specifically requested aggregate data — information that would not identify individual patients.

Data 52

Data Treatment Patients Chronic Pain 52

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

Veriheal

SEPTEMBER 30, 2021

Cancer patients arguably stand to benefit the most from cannabis’ unique properties and benefits, such as anti-nausea, anti-inflammation, reduced pain, inhibited tumor growth, and appetite stimulation. Even still, the “odds of a cancer patient using marijuana in the past year were essentially flat between 2013 and 2018.”

Patients 98

Patients Research and Development Treatment Consumption 98

Healer

JANUARY 19, 2021

The objective of this study was to determine how the use of medical cannabis affects prescribed opioid usage in chronic pain patients. Healer conducted an online convenience sample survey of patients from three medical cannabis practice sites who had reported using opioids. Read full published study.

Treatment 98

Treatment Data Chronic Pain Patients 98

Cannabis Law Report

JULY 2, 2022

reported a data breach stemming from a misconfigured web application that caused personal information to be accessible on the company’s website. On June 17, 2022, Silverstreak filed an official notice of the breach and sent out data breach letters to all affected parties. What We Know About the Silverstreak Solutions Data Breach.

Data 52

Data Access Topical Cannabis 52

Veriheal

DECEMBER 14, 2021

An Analysis of Nationwide EVALI Data. Additionally, this one policy change made the odds of vaping as the primary form of consumption 40% lower, demonstrating that patients were ready and willing to switch from vaping to smoking home-grown cannabis once they were able.

Data 98

Data Vaping Legalization Consumption 98

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Declining circulating tumor cell (CTC) count in treated patients.

Data 100

Data Research and Development Clinical Trials Therapy 100

NORML

NOVEMBER 1, 2019

Those suffering from chronic pain report significant improvements in health following the passage of medical cannabis access laws, according to data published in the journal Forum for Health Economics & Policy. Among state-licensed medical cannabis registrants, two out of three report consuming cannabis to mitigate pain conditions.

Access 170

Access Patients Chronic Pain Law 170

Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. To date, Veriheal’s global team has helped hundreds of thousands of patients gain access to medical cannabis.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

CannaMD

NOVEMBER 4, 2020

According to a recent study published in the Journal of Headache Pain , across 2,032 patients and 21 illnesses, headache was a symptom treated with cannabis in 24.9% (505) of cases, while 88% (445) of headache patients treated probable migraines with cannabis. 30 percent of migraine patients in the U.S. The results?

Patients 105

Patients Chronic Pain Marijuana Research and Development 105

NORML

APRIL 6, 2020

A team of researchers affiliated with the University of Miami School of Nursing are collecting epidemiological data to better evaluate how cannabis consumers, and patients in particular, are responding to the COVID-19 pandemic. So, we are combining our skills to do our part to provide that data. Vidot, who is leading the study.

Data 278

Data Access Patients Collective 278

NORML

DECEMBER 6, 2019

The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Subjects receiving treatment reported no adverse effects.

Clinical Trials 107

Clinical Trials Patients CBD Therapy 107

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. There were three Cohorts, with 12 patients in each cohort. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

CannaMD

MARCH 4, 2020

Releaf is a free mobile app to help patients track, learn from, and improve their use of medical cannabis. The data that is collected in Releaf App is used for multiple research studies and helps physicians identify what products patients are finding most effective. Patients can learn more by visiting ReleafApp.com.

Patients 81

Patients Data Collective Treatment 81

Cannabis Law Report

SEPTEMBER 6, 2022

WHILE Italy is both one of the earliest and largest medical cannabis markets in Europe, new data has revealed the ongoing inability of its system to ‘serve patients’ needs’. The Italian Military’s Monopoly On Medical Cannabis Production Is Strangling Market Growth New Data Suggests. Undersupply. Read full article.

Data 52

Data Patients Cultivation Cannabis 52

Cannabis Law Report

NOVEMBER 2, 2022

Cannabis Health Website reports New survey data reveals the myriad of issues facing UK patients, four years on from the legalisation of medical cannabis. Data collected from a recent survey paints a mixed picture of the experience of medical cannabis patients in the UK.

Patients 52

Patients Advocacy Data Collective 52

Cannabis Law Report

MARCH 31, 2022

South Dakota started approving medical cannabis patient and physician applications but at a rate that could make it difficult for patients to connect with doctors registered for the program. South Dakota Now Approving Medical Cannabis Patients and Physicians. Full report.

Patients 52

Patients Programs Data Cannabis 52

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Joint Blog

MARCH 7, 2021

A new study titled Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial has found that inhaling herbal marijauna is associated with clinical improvements and increased quality of life in patients with mild to moderate ulcerative colitis (UC). The study included 32 patients.

Patients 37

Patients Data Treatment THC 37